Inbiomotion develops the MAF test, a single‑gene predictive biomarker diagnostic intended to identify early breast cancer patients who would benefit from adjuvant bisphosphonate therapy. The test has been technically and analytically validated and produced supportive results using archived samples from the AZURE and NSABP B-34 trials. Inbiomotion holds more than 180 patents and patent applications covering the MAF test and related uses. The company plans to complete regulatory validation and begin commercialisation of the MAF test in 2022. The product targets a global market for complementary diagnostics in early breast cancer and aims to improve personalized adjuvant treatment and reduce metastatic relapse risk. Founded in 2010 as a spin‑off of IRB Barcelona and ICREA, Inbiomotion leverages academic research in metastasis to advance its clinical diagnostic. Inbiomotion develops diagnostic tests, notably Osteomet, to predict the risk that prostate and breast cancer patients may suffer bone metastasis. Osteomet has been validated in over 1,300 patient samples from independent cohorts in multiple countries. The company is a spin-off of the Institut de Recerca Biomèdica de Barcelona (IRB Barcelona) and ICREA and is led scientifically by Dr. Roger Gomis. Founded in 2012 and based in Barcelona, Inbiomotion targets patients for whom bone is the most common site of metastasis. Its main objective is to complete clinical and regulatory development of its tests within the next two years. The company recently secured new funding to advance those development plans. Inbiomotion is a spin-off from IRB Barcelona and ICREA focused on developing an assay to predict future bone metastases in cancer patients. Its core product is a predictive marker that has been validated on more than 900 patient samples across two independent studies using gene expression and immunohistochemistry, demonstrating a 95% negative predictive value. The company aims to enable patient risk stratification to guide preventive treatment decisions and improve clinical management and healthcare efficiency. Funds from the financing round will be used to validate the marker through multiple clinical studies in Barcelona and England and to advance development toward regulatory approval. Inbiomotion is based in the Parc Científic de Barcelona and was founded by Dr. Roger Gomis.

Total raised

$5M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2016